Universität zu Köln

Seifert, Harald ORCID: 0000-0002-7732-4762, Blondeau, Joseph, Lucassen, Kai ORCID: 0000-0002-6335-7731 and Utt, Eric A. (2022). Global update on the in vitro activity of tigecycline and comparators against isolates of Acinetobacter baumannii and rates of resistant phenotypes (2016-2018). J. Glob. Antimicrob. Resist., 31. S. 82 - 90. OXFORD: ELSEVIER SCI LTD. ISSN 2213-7173

Full text not available from this repository.

Abstract

Objectives: This study presents 2016-2018 in vitro antimicrobial activity data and rates of resistant phenotypes for clinical isolates of Acinetobacter baumannii from Africa/Middle East, Asia/South Pacific, Europe, Latin America, and North America. Methods: A total of 4320 A. baumannii isolates were collected across all regions between 2016 and 2018. The in vitro antimicrobial activities of amikacin, colistin, levofloxacin, meropenem, and tigecycline were determined using the broth microdilution methodology of the Clinical and Laboratory Standards Institute. MICs were interpreted using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (version 11.0). Rates of subsets that were resistant to amikacin, colistin, levofloxacin, and meropenem, according to EUCAST breakpoints, are also presented. Results: In each region, tigecycline and colistin were active against isolates of A. baumannii (MIC 90 values, 1 or 2 mg/L) and the lowest rate of resistance was to colistin (1.2%-7.3%). The rates of resistance to the panel of agents were generally lower among A. baumannii from North America (1.3%-42.7%), compared with the other regions. Fewer than 11% of meropenem-resistant A. baumannii were also resistant to colistin. The rates of amikacin-, levofloxacin- and meropenem-resistant A. baumannii were lowest in North America and mostly higher in Africa/Middle East and Latin America. Conclusion: In each geographical region, tigecycline and colistin maintained good in vitro antimicrobial activity against isolates of A. baumannii , including antimicrobial-resistant subsets. The higher rates of meropenem-resistant isolates, particularly in Africa/Middle East and Latin America, require continued monitoring because of the scarcity of effective treatment options. (c) 2022 The Pfizer Inc and The Author(s). Published by Elsevier Ltd. On behalf of International Society ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Seifert, Harald UNSPECIFIED orcid.org/0000-0002-7732-4762 UNSPECIFIED Blondeau, Joseph UNSPECIFIED UNSPECIFIED UNSPECIFIED Lucassen, Kai UNSPECIFIED orcid.org/0000-0002-6335-7731 UNSPECIFIED Utt, Eric A. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-677819
DOI:	10.1016/j.jgar.2022.08.002
Journal or Publication Title:	J. Glob. Antimicrob. Resist.
Volume:	31
Page Range:	S. 82 - 90
Date:	2022
Publisher:	ELSEVIER SCI LTD
Place of Publication:	OXFORD
ISSN:	2213-7173
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language SURVEILLANCE Multiple languages Infectious Diseases; Pharmacology & Pharmacy Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/67781